Kelley Boucher - 28 Jan 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief People Officer
Signature
/s/ David Watson, attorney-in-fact for Kelley Boucher
Issuer symbol
APLS
Transactions as of
28 Jan 2026
Net transactions value
$0
Form type
4
Filing time
30 Jan 2026, 16:13:32 UTC
Previous filing
03 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boucher Kelley Chief People Officer C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM /s/ David Watson, attorney-in-fact for Kelley Boucher 30 Jan 2026 0002070437

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +30,146 +31% $0.000000 127,804 28 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.